CircPTK2 inhibits cell cisplatin (CDDP) resistance by targeting miR-942/TRIM16 axis in non-small cell lung cancer (NSCLC)
Author:
Affiliation:
1. Department of Cardiothoracic Surgery, The Second People’s Hospital of Yibin, Yibin, Sichuna, China
Funder
there is no funding associated with the work
Publisher
Informa UK Limited
Subject
Applied Microbiology and Biotechnology,General Medicine,Bioengineering,Biotechnology
Link
https://www.tandfonline.com/doi/pdf/10.1080/21655979.2021.2024321
Reference60 articles.
1. Lung Cancer 2020
2. Small Cell Lung Cancer
3. Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01)
4. Effects of Concomitant Cisplatin and Radiotherapy on Inoperable Non-Small-Cell Lung Cancer
5. Circular RNAs: Identification, biogenesis and function
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Circular RNAs in lung cancer: implications for preventing therapeutic resistance;eBioMedicine;2024-09
2. Circ_0001786 facilitates gefitinib resistance and malignant progression in non-small cell lung cancer via miR-34b-5p/SRSF1;Journal of Cardiothoracic Surgery;2024-04-05
3. Lactate promoted cisplatin resistance in NSCLC by modulating the m6A modification-mediated FOXO3/MAGI1-IT1/miR-664b-3p/IL-6R axis;Neoplasia;2024-02
4. Non-Coding RNAs as Key Regulators in Lung Cancer;International Journal of Molecular Sciences;2023-12-31
5. Emerging role of competing endogenous RNA in lung cancer drug resistance;Journal of Chemotherapy;2023-12-20
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3